Laura Joszt, MA

Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.

The Trump administration advances the Most Favored Nation order by partnering with Pfizer, which came to the table voluntarily and has been granted a reprieve from upcoming drug tariffs.

The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies.

Patients with acute myeloid leukemia (AML) in remission for over 3 years experience survival rates comparable with a matched cohort from the general population.

The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.

The subcutaneous dose had comparable efficacy to intravenous dosing while enhancing patient convenience in non–small cell lung cancer, explains Nicolas Girard, MD, PhD.

Subcutaneous amivantamab plus chemotherapy offers an equally effective treatment for EGFR exon 20 insertion non–small cell lung cancer (NSCLC), mirroring PAPILLON results of the intravenous formulation, explained Sun Lim Min, MD, PhD.

Disparities in lung cancer biomarker testing show barriers that delay diagnosis and treatment for lower-income patients, according to Sandip P. Patel, MD.

Personalized testing is preferred for patients with NSCLC with mutations, but there are challenges to implementing this testing, said Yang Xia, MD, PhD.

Pediatric dermatology faces access disparities due to lack of awareness, language barriers, and training gaps in recognizing diverse skin conditions.

Broad COVID-19 vaccination proves economically beneficial, especially for older adults, highlighting significant health and financial advantages.

Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.

During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.

Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.

In a webinar, experts discussed cardiovascular disease prevention strategies, emphasizing personalized risk assessments and emerging treatments to combat this health crisis.

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

Revumenib is now the sole targeted therapy recommended by the National Comprehensive Cancer Network for KMT2A-rearranged acute leukemia, which opens a path for payers, said Ivo Abraham, PhD, RN, of The University of Arizona.

During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.

Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.

In a webinar, panelists discuss Trump's 2025 drug pricing policies, focusing on the Most Favored Nation order, pharmacy benefit manager reform, and implications for manufacturers and patients.

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, says Mansi Shah, MD.

Revumenib, an oral targeted therapy for rare leukemias, is projected to be cost-neutral for health plans over 3 years, primarily due to lower administration costs and improved patient quality of life, said Ivo Abraham, PhD, RN, of The University of Arizona.

Caregivers and patients with acute leukemia face unique challenges, prioritizing treatment preferences that impact quality of life and emotional well-being.

Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple myeloma.

Revumenib for relapsed/refractory acute leukemias with KMT2A translocation is cost-neutral for health plans, but traditional methods of analysis may not be accurate for rare diseases, said Ivo Abraham, PhD, RN, of The University of Arizona.

Delivering value-based cancer care requires overcoming hurdles to access care and tailoring care that prioritizes the quality-of-life metrics the patient values, explained Coral Omene, MD, PhD.

Coverage from IVBM Cleveland, held May 15, 2025.